Kawasaki disease (KD) is a diffuse and acute small-vessel vasculitis observed in children, and has genetic and autoimmune components. We genotyped 112 case-parent trios of European decent (confirmed by ancestry informative markers) using the immunoChip array, and performed association analyses with susceptibility to KD and intravenous immunoglobulin (IVIG) nonresponse. KD susceptibility was assessed using the transmission disequilibrium test, whereas IVIG non-response was evaluated using multivariable logistic regression analysis. We replicated single-nucleotide polymorphisms (SNPs) in three gene regions (FCGR, CD40/CDH22 and HLA-DQB2/HLA-DOB) that have been previously associated with KD and provide support to other findings of several novel SNPs in genes with a potential pathway in KD pathogenesis. SNP rs838143 in the 3′-untranslated region of the FUT1 gene (2.7 × 10 − 5 ) and rs9847915 in the intergenic region of LOC730109 | BRD7P2 (6.81 × 10 − 7 ) were the top hits for KD susceptibility in additive and dominant models, respectively. The top hits for IVIG responsiveness were rs1200332 in the intergenic region of BAZ1A | C14orf19 (1.4 × 10 − 4 ) and rs4889606 in the intron of the STX1B gene (6.95 × 10 − 5 ) in additive and dominant models, respectively. Our study suggests that genes and biological pathways involved in autoimmune diseases have an important role in the pathogenesis of KD and IVIG response mechanism.
INTRODUCTION
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the United States. It is a potentially lifethreatening acute vasculitis with diffuse involvement of multiple organ systems 1 and has a predilection for the coronary arteries. In the United States, about 5500 cases were estimated in 2009 by passive surveillance alone; 2 and based on the system dynamics modeling simulations, there will be an average of 6200 new patients per year and a total of 161 776 individuals (half of them adults) with a history of KD by 2030. 3 The disease is primarily associated with the East Asian populations, although there has been an increase in the incidence of KD among European-Americans over the last two decades. 4 The primary treatment of KD is the administration of intravenous immunoglobulins (IVIG) accompanied by aspirin. 5 Approximately 15-25% of the cases require more than a single dose of IVIG therapy to achieve complete resolution. 5 Furthermore, coronary artery aneurysms develop in 15-25% untreated cases compared with o5% among those treated, although a substantially higher percentage show coronary artery dilation. 5 KD, also known as mucocutaneous lymph node syndrome, is considered an autoimmune disease, as walls of the blood vessels are inflamed throughout the body with damage to coronary arteries likely mediated by auto-antibodies to endothelial cells (ECs). 6 Parental KD is also considered a risk factor with the odds of KD among siblings and recurrent cases being seven and three times higher of KD probands and parents with history of KD, respectively, compared with the general population, 7 suggesting a genetic etiology. However, genetic studies, including genomewide association studies are often inconsistent and the associations are often race or ethnicity specific. Furthermore, only few candidate gene studies, including ours, have assessed the gene-IVIG non-response association. [8] [9] [10] [11] [12] Our objective was to fine-map regions of immune-related genes using the Human ImmunoChip to validate the association of immune-related genes with susceptibility to KD, search for novel single-nucleotide polymorphisms (SNPs), examine shared loci with other autoimmune diseases and perform genetic evaluation for IVIG treatment response among European-American case-parent trios.
RESULTS
The average age of the probands was 45.7 (±32.3) months, with the average age for the responders being 44.8 (±30.8) months and the non-responders being 46.6 (±33.9) months. Overall, the study population consisted of 56.1% male probands, 48.1% males being responders and 64.2% being non-responders.
Susceptibility to KD The Manhattan plots corresponding to the P-values for the SNPs in the transmission disequilibrium test (TDT) test are presented in Figure 1a for the additive model and Figure 1b for Figure S3 show the linkage disequilibrium (LD) plot for regions with multiple hits in chromosomes 1, 5 and 19) . In the additive model, the top SNPs were predominantly located in chromosome 19, largely located in regions of galactoside 2-alpha-Lfucosyltransferase 1 (FUT1) gene and Ras-interacting protein 1 (RASIP1) gene (Table 1) , but not in the region of inositol-trisphosphate 3-kinase C (ITPKC), another gene located on chromosome 19 that has been previously linked to KD. The topmost SNP (rs838143) and two other more common SNPs (rs838142 and rs4021), all in the untranslated region (UTR) of the FUT1 gene, were significantly over-transmitted from the parents to KD children (P = 2.70 × 10 -5 , 4.80 × 10 − 5 , 1.18 × 10 − 4 , respectively).
In the dominant model, rs9847915 in the intergenic region between LOC730109 and Bromodomain containing 7 Pseudogene 2 (BRD7P2) on chromosome 3 was the topmost SNP significantly (Table 1 , lower panel). However, association of SNPs was largely observed in genes on chromosome 1, in the region of the FCGR gene family cluster.
IVIG response
The Manhattan plots that summarize the associations between each SNP and response to IVIG treatments are presented in Figure 2a for the additive model, and Figure 2b for the dominant model (quantile-quantile plots in Supplementary Figures S2a  and b ). The top 15 associated SNPs are presented in Table 2, upper  panel for additive model and lower panel for dominant model (all  results in Supplementary Table 2 and Supplementary Figure S3 show the LD plot for regions with multiple hits in chromosomes 6 and 16). In the additive model, intergenic variant rs1200332 between the bromodomain adjacent to the zinc-finger domain, 1A (BAZ1A), and C14orf19 genes on chromosome 14 was the topmost significantly associated SNP with response to IVIG treatment. The odds of not responding to IVIG treatment was five times higher in those with the minor allele T (odds ratio-non-responders: 5.49, P = 1.40 × 10 − 4 ) compared with the wild-type C allele. On the other hand, individuals with a minor allele at SNPs rs6017164, rs72945401, rs7579420, rs7163190, rs3134926, rs3777914, rs1883137 and rs11641163 had higher odds of responding to IVIG, and most of these responders had minor allele frequency (MAF) closer to the reported frequency for HapMap Caucasians ( Table 2) . Several SNPs on chromosome 6 were also found to be significantly associated with IVIG responsiveness in or around G-protein-coupled receptor-6 (GPR6)/Wiskott-Aldrich syndrome protein family, member 1 (WASF1), protein reversionless 3-like (REV3L), neurogenic locus notch homolog protein 4 (NOTCH4)/ C6orf10 and tumor necrosis factor receptor family 3-interacting protein 2 (TRAF3IP2) genes.
The top SNPs associated with response to IVIG treatment using the dominant model were predominantly located on chromosome 16 and several of them were in LD ( Table 2 , lower panel). The top most significant SNP was rs4889606, located in the intronic region of the syntaxin 1B (STX1B) gene on chromosome 16 and in LD with rs9926533. This SNP was associated with a lower odds of IVIG nonresponse among those carrying the minor allele G (odds rationon-responders: 0.13, P = 6.95 × 10 − 5 ) compared with the wildtype 'A' allele. Other SNPs located on chromosome 16 were found either in the intronic or intergenic regions of SET domaincontaining protein 1A (SETD1A), F-box and leucine-rich repeat protein 19 (FBXL19), cardiotrophin-1 (CTF1)/LOC283932 and syntaxin 1B and 4 (STX1B/STX4) or STX4/ zinc-finger protein 668 (ZNF668) genes, and all were associated with higher odds of response to IVIG treatment.
DISCUSSIONS
In the present study, we evaluated the genetic association of susceptibility to KD and IVIG treatment response using the ImmunoChip in homogenous European-American case-parent trios. Although the sample size was relatively small, several SNPs from previous studies were replicated in our family-based study, strengthening our results. Furthermore, these replicated SNPs along with few of the top significant SNPs in our current study were found to be expression quantitative trait loci (eQTLs) for Minor allele was always used as the risk allele in the analysis.
High-density genotyping of immune loci in KD specific genes, and are therefore more likely to have a functional role in the regulation of genes and their expression, and subsequent immune response to KD. Consequently, we discuss these SNPs in addition to some of the SNPs that were highly significantly in our study and have shown previous associations with autoimmune diseases. Two SNPs, rs2857151, in the intergenic region of the human leukocyte antigen class II histocompatibility antigen, DQ beta 2 chain and DO beta (HLA-DQB2 and HLA-DOB), and rs4813003, downstream of tumor necrosis factor receptor superfamily member 5 (TNFRSF5) or B-cell-associated molecule CD40 (CD40) gene, that were previously reported in genome-wide association studies to be associated with KD were replicated (Table 3 ). 13 SNP rs2857151 was shown to be an eQTL for several of the human leukocyte antigen genes, namely, HLA-DOB, -DRB1, -DRB5, -DQA1, -DQA2 and transporter 2, ATP-binding cassette, sub-family B (TAP2). 14 SNP rs4813003 was shown to be an eQTL for the CD40 gene. 14, 15 SNP rs2857151 in combination with rs4813003 and another locus in a three-locus model were previously shown to confer the highest risk for KD, whereas the same SNP with rs1801274 was shown to confer the highest risk for coronary artery lesions. 13 The compound effect was hypothesized to provide evidence for the additive effect of these loci on KD. SNPs within the TAP2 gene have also been associated with autoimmune diseases such as rheumatoid arthritis (RA), ankylosing spondylitis and multiple sclerosis, and the TAP2 proteins are known to have an important role in antigen presentation. [16] [17] [18] [19] SNP rs4813003 is located in the intergenic region between the CD40 and the cadherin 22 (CDH22) genes. CD40 is a receptor protein, which is part of the tumor necrosis factor receptor superfamily and is expressed on B cells, monocytes, dendritic cells, ECs and epithelial cells. 20 It interacts with the CD40 ligand on the T-helper cells and mediates immune and inflammatory responses. CD40 was also recently observed to facilitate damage to ECs through an inflammatory response mounted via activated platelets and the expression of adhesion molecules. 20 On the other hand, CDH22 is a type of cadherin, part of a superfamily of transmembrane proteins, and is known to mediate cell-to-cell adhesion in a calcium-dependent manner. Altered expression of CDH22 has been previously associated with cell proliferation, invasiveness and metastasis in certain cancers. 21 Previously, we had independently shown that rs1801274 in FCGR2A gene is associated with KD susceptibility in European-Americans, 9, 11 confirming similar findings from a genome-wide association study. 22 Multiple variants in the FCGR gene family cluster within the ImmunoChip were also associated with KD susceptibility in our TDT analysis with a dominant inheritance, with SNPs in both the intronic and intergenic regions associated with KD susceptibility. This gene region is consistent with our previous studies of KD. [9] [10] [11] These findings are encouraging, specifically as results from several genome-wide association studies studies have been replicated in only few studies using independent cohorts. 23, 24 Polymorphisms and copy-number variation of FCGR genes are also associated with susceptibility High-density genotyping of immune loci in KD for autoimmune diseases such as RA and systemic lupus erythematosus. Accordingly, an intersection could potentially exist between KD and other autoimmune disorders. Although the function of several genes in Table 1 is unknown or unconfirmed, few (FUT1, RASIP1 and BRD7P2) are noteworthy and could have potential biological mechanisms in the KD pathway. The SNPs significantly associated with KD in the additive model were located in the 3′-UTR region of the FUT1 gene, the intronic region of the RASIP1 gene and the intergenic region of the BRD7P2 gene. FUT1 encodes the galactoside 2-alpha-L-fucosyltransferase 1 enzyme that is involved in the formation of the H antigen on erythroid cells, regulating the expression of ABO antigens. 25, 26 FUT1 has a major role in the pathogenesis of RA and is involved in angiogenesis, cell adhesion and cell proliferation of various inflammatory cells. 27 This role is further supported by experiments showing inactivation of FUT1 using short interfering RNA where reduction in cell proliferation and tumor growth were observed, as well as migration of ECs and integration with the extracellular matrix. [28] [29] [30] Macrophages are also reported to modulate the expression of FUT1 and FUT2 through the interleukin-6 signaling pathway in epithelial cells of the endometrium to enable implantation of the embryo, and increased levels of macrophages are potentially associated with inflammatory response. 31 The three SNPs from our study are located in the 3′-UTR of FUT1, and interestingly, MAF for all three was higher in HapMap Asians compared with Caucasians, but the same allele was the wild-type allele in Yoruban Africans. Although the functions of these SNPs are not yet known, future studies could facilitate this by evaluating the potential binding sites of microRNAs in the 3′-UTR in relation to these variants. The RASIP1 gene encodes the RASIP1 protein that has been associated with tubulogenesis and angiogenesis in as early as the embryonic stage, and is specific to the endothelium. 32 Lumen formation via RASIP1 occurs through the regulation of the Rho family of monomeric G proteins, requiring the suppression of RhoA and activation of Cdc42 and Rac1 proteins. 33 RASIP1-deficient vessels are shown to collapse, as EC adhesion to the extracellular matrix is lacking. 33 RASIP1 variants have been associated with early microvascular disease, which is a predictor of incident cardiovascular disease, and Crohn's disease in conjunction with FUT2. 34, 35 Thus it may have a more important role in the pathogenesis of both KD and coronary artery lesions. SNP rs9847915 in the BRD7P2 gene was associated with susceptibility to KD in our study; the MAF for this SNP is lowest among Africans, but similar for Asians and Caucasians from HAPMAP. This gene has been associated with phenotypes such as Behcet's syndrome, which also involves systemic vasculitis of small vessels with an autoimmune component, similar to KD. 36 To date, IVIG responsiveness has not yet been evaluated using large-scale genotyping arrays. Even with a smaller sample size, several genes (BAZ1A, GPR6, TRAF3IP2, REV3L, STX1B, STX4 and CTF1), listed in Table 2 , are noteworthy as working mechanisms of IVIG therapy have yet to be fully elucidated. In addition, SNP rs1200332 was shown to be an eQTL for chromosome 14 openreading frames 10 and 24 (C14orf10 and C14orf24), and SNP rs10871454 as an eQTL for ZNF668, STX4 and SETD1A among others. 14 In the additive model, SNPs located in the intergenic region of the BAZ1A gene, the 3′-UTR and intergenic regions of the GPR6 gene and the intronic regions of the TRAF3IP2 gene were significantly associated with IVIG responsiveness. The SNP rs1200332 in the intergenic region of BAZ1A and C14orf19 genes has been associated with Crohn's disease, an autoimmune disease, in Puerto Ricans. 37 The MAF of rs1200332 is higher among Africans, but lower and similar across Caucasians and Asians in HAPMAP. The BAZ1A gene encodes a subunit of the ATP-dependent chromatin assembly factor, which is part of the chromatic remodeling complex and is involved in DNA damage response and repair. 38 The GPR6 gene encodes the GPR6 protein that is expressed on vascular smooth muscles cells and ECs, and is an orphan GPCR modulated by sphingosine-1 phosphate, an important regulator in the vascular system. 39 The higher odds of non-response with the SNPs in BAZ1A and GPR6 may be a result of impaired damage response and higher propensity to coronary lesions, respectively. The TRAF3IP2 gene codes for the TRAF3-interacting protein 2, also known as activator 1, that acts as a signaling adaptor in interleukin-17-mediated cellular immune responses through nuclear factor κ-B activation, or as a negative regulator by inhibiting CD40 and B-cell-activating factor receptor-mediated signaling. 40 The negative regulation of CD40 may be one mechanism through which the TRAF3IP2 SNPs are mediating response to IVIG. TRAF3IP2 has also been associated with autoimmune disorders, such as psoriasis and systemic lupus erythematosus, and is speculated to bring about loss of the negative regulatory role of activator 1 in systemic lupus erythematosus resulting in B-cell hyperplasia and enhanced survival of autoreactive B cells. 40 In the dominant model, most SNPs associated were in chromosome 16 in the intronic and intergenic regions of the STX gene family; the top SNP rs4889606 in the STX1B gene having the lowest MAF among Africans, but the same minor allele being the wild-type allele among Asians from HAPMAP. In general, the interaction of syntaxin with synaptotagmin results in fusion of the vesicular and plasma membranes and subsequent exocytosis. 41 Smirnova et al. 42 speculated that syntaxin may be involved in the Lambert-Eaton syndrome, an autoimmune disorder associated with some small-cell lung cancers resulting in antibodies against synaptotagmin and calcium channels. Several SNPs within the intronic and intergenic region of the STX4 gene were also associated with increased IVIG response. The STX4 gene encodes for STX4, which is also part of the syntaxin family of membrane integrated proteins. 43 STX4 has an important role in the regulation of secretions from various immune cells including neutrophils, macrophages and eosinophils. 44 The addition of short interfering RNAs against STX4 has been shown to reduce immunoglobulin E antibody exocytosis from plasma cells from several cell lines. 43 It was additionally shown that STX4 knockdown results in reduced secretion of tumor necrosis factor-α from macrophages. 44 SNPs in the intergenic region of the CTF1 gene were also significantly associated with IVIG responsiveness. The CTF1 gene encodes for the CTF1 protein, which is part of the interleukin-6 family and is involved in cell proliferation, cell migration and collagen production. CTF1 is largely localized to the ECs and vascular smooth muscle cells, with genetic variations in the gene associated with dilated cardiomyopathy or hypertension-related left ventricular hypertrophy. [45] [46] [47] CTF1 has been shown to have both beneficial as well as detrimental effects based on which signaling pathway is induced as it has been associated with wound healing in myocardial infarction and prevention of apoptosis due to hypoxia, as well as plaque instability and pathophysiology of atherosclerosis. 48, 49 The reduced pro-inflammatory secretions and the anti-inflammatory response as a result of the STX and CTF-1 SNPs, respectively, may be one of the ways in which improved IVIG response is enabled. The role of all these genes in susceptibility to KD and IVIG response could potentially be mediated through various immunity signaling pathways.
There are several strengths to our study. Sample size was relatively small in our study and thus the findings in our study are preliminary; however, considering that KD is rare (13.7 per 100 000 among whites o5 years) 4 and only 15-25% do not respond to IVIG treatment, the difficulty in assembly of trios for this study should be appreciable. The trio-based family analysis using TDT is robust to factors such as confounding and variance inflation, which enabled us to confirm and replicate previous findings related to KD susceptibility despite the small sample size of our study. In addition, we determined ethnicity based on ancestry informative markers and performed the analysis in confirmed European-Americans, accounting for population stratification and thus ensuring a homogenous population.
Our study is not without limitations. Of note, we included equal number of IVIG responders and non-responders for the TDT analysis; thus, some of the findings could be biased toward less frequent IVIG responders in the population, as they were preferentially included in the analyses. The ImmunoChip largely includes genes that were associated with several autoimmune disorders and was therefore ideal for testing genetic associations with KD, but does not represent the whole spectrum of SNPs and genes that may be involved in immune response. As a result, the density of markers found on the ImmunoChip is not as high as opposed to fine mapping of gene regions, and thus the SNPs associated in our study may be tagging one or more SNPs in LD and/or possibly the true causal variants. Lastly, we largely describe SNPs in the UTR and intronic regions, although we acknowledge that variants from other parts of the region can be functional and related to distant genes. 50 And although we include discussion of certain SNPs as eQTLs for some genes, we recognize that we were limited by the annotations provided by the ImmunoChip consortium and express caution in interpreting these results, as certain eQTLs are reported in relation to specific cells and therefore may not be generalizable or applicable in the context of KD.
In the current study, we took a hypothesis-free agnostic approach to show that several SNPs in immune-related genes included in the ImmunoChip are associated with susceptibility to KD and IVIG response. Some of these genetic associations have not yet been reported and can be potentially involved in KD pathogenesis, whereas some of these genes are known to be in the pathway of other known autoimmune diseases. Future studies are therefore needed to replicate these findings, and further finemapping is required to identify biologically causal SNPs as well as their functions in relation to either KD susceptibility or IVIG response mechanisms.
PATIENTS AND METHODS

Study population
The current study included 112 case-parent trios of European-American descent from a retrospective cohort of KD. The study cohort has been described in detail previously. 11 Briefly, the probands (55 IVIG responders and 55 non-responders) were identified through clinical or hospital databases and then cross-referenced with the echocardiography databases of the respective heart centers. The probands were enrolled from children's hospitals at three locations: Seattle, WA, USA; Oakland, CA, USA; and Salt Lake City, UT, USA. The study was approved by the institutional review board at each of the participating institutions, and informed consent was obtained from the parents.
Clinical outcomes
Kawasaki disease. KD was defined based on the guidelines recommended by the American Heart Association and the American Academy of Pediatrics. 10, 51 The standard epidemiological criteria require the presence of fever for ⩾ 5 days and at least four of five clinical features to make the diagnosis of KD. Participants in our study were included based on the initial criteria, but we also included those with at least two clinical features accompanied by coronary artery involvement.
Response to IVIG. The treatment of KD included administration of an intravenous infusion of Immunoglobulin at 2 g kg − 1 along with aspirin within 10 days of the onset of fever. Non-response, or refractoriness to the initial IVIG therapy was characterized by the presence of persistent fever (⩾38°C) at ⩾ 36 h or recurrence of fever (⩾38°C) at ⩾ 36 h. 51 DNA extraction, genotyping and quality control As previously described, genomic DNA was extracted from blood or saliva samples obtained from the probands and their biological parents using the Versagene DNA purification kit (Gentra Systems, Minneapolis, MN, USA). 11 The PicoGreen assay for double-stranded DNA was used for quantification and the final concentration was adjusted to 100 ng μl − 1 in Tris-EDTA.
Genotyping was performed using the ImmunoChip, an iSelect HD custom genotyping array (Illumina, San Diego CA, USA), developed by the ImmunoChip Consortium. 52 The ImmunoChip contains 195 806 SNPs and 718 small insertions-deletions, of which 5001 are non-synonymous coding, 1926 are synonymous coding, 4065 located in the UTR and the rest fall either in the intronic, intergenic or undefined regions. The loci were selected on the basis of their associations with autoimmune or inflammatory diseases, and ImmunoChip was designed using early 1000 Genome Pilot data (February 2010 release). 52, 53 For genotype calling purposes, the data were analyzed using the Genome Studio Genotyping Module (Illumina) using the NCBI build 36 (hg18) map. The normalized probe intensities were extracted for all samples that passed standard laboratory quality-control thresholds. Further quality control included examining the SNPs for missingness by SNP and by individual, deviations from Hardy-Weinberg equilibrium at a P-value o0.001 and minor allele frequencies o0.05. Of a total 195 806 SNPs, there were 191 475 in the autosomal chromosomes. A total of 36 individuals were excluded as a result of missing 410% genotype data, of which three were probands and the rest were parents. Similarly, 16 220 SNPs were excluded as they were missing genotype data in 410% of the sample population. In addition, deviation from Hardy-Weinberg equilibrium was observed in 477 SNPs whereas 68 761 SNPs had MAFo0.05 and therefore these SNPs were excluded from the analysis.
Statistical methods
TDT was employed to assess susceptibility to KD using the family-based association test, as described previously. 11 Briefly, parent-child trios were evaluated for differential transmission of alleles from heterozygous parents to the affected child. Single-marker analysis was conducted to test the association under the null hypothesis of no linkage and no association using both additive and dominant genetic models. The direction and frequency of transmission is provided through the Z statistic and P-values.
The genetic association of response to IVIG treatment was assessed by implementing a case-control approach (responders versus nonresponders) and performing logistic regression analyses adjusting for age and first two principal components, using both additive and dominant models in PLINK (v1.07) (Harvard University, Cambridge, MA, USA). 54 European-American ancestry of all parents and probands was confirmed using 155 ancestry informative markers in EIGENSTRAT. 10, 11, 55 Quantilequantile and Manhattan plots, based on P-values, were created using SAS 9.3 (SAS Institute Inc., Cary, NC, USA) to evaluate deviations of the observed test statistics distribution from the expected one and to visualize the association results, respectively.
